Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) Return on Equity (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Return on Equity for 5 consecutive years, with 0.39% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity rose 1204.0% year-over-year to 0.39%, compared with a TTM value of 0.39% through Dec 2025, up 1204.0%, and an annual FY2025 reading of 1.97%, up 219.0% over the prior year.
  • Return on Equity was 0.39% for Q4 2025 at Aligos Therapeutics, up from 1.0% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.39% in Q4 2025 and bottomed at 12.42% in Q4 2024.
  • Average Return on Equity over 5 years is 1.65%, with a median of 1.0% recorded in 2025.
  • The sharpest move saw Return on Equity plummeted -1123bps in 2024, then skyrocketed 1204bps in 2025.
  • Year by year, Return on Equity stood at 0.64% in 2021, then plummeted by -33bps to 0.85% in 2022, then tumbled by -40bps to 1.19% in 2023, then tumbled by -941bps to 12.42% in 2024, then soared by 97bps to 0.39% in 2025.
  • Business Quant data shows Return on Equity for ALGS at 0.39% in Q4 2025, 1.0% in Q3 2025, and 0.68% in Q2 2025.